(RTTNews) - Exact Sciences Corp. (EXAS), Friday announced the landmark clinical results from its ALTUS study, showing that the Oncoguard Liver blood test significantly outperforms ultrasound in ...
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups Exact Sciences Corp.
A new scoring system using common clinical parameters accurately identifies chronic liver disease patients with a significantly increased risk of developing liver cancer. This tool acts as a universal ...
Scientists identify measurable cellular changes that flag higher cancer risk more than a decade before tumors appear. In A ...
Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...
Oncoguard® Liver blood test delivers six times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care. These findings will be presented as late-breaking data ...